Corrigendum to “Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer” (EBioMedicine Aug 2016; 10: 124–36) (S2352396416303243) (10.1016/j.ebiom.2016.07.019))
Journal
EBioMedicine
Journal Volume
26
Pages
198-199
Date Issued
2017
Author(s)
Abstract
An earlier online version of the paper (EBioMedicine. Aug 2016; 10: 124�V36) contained some inadvertent mismatches between inset and enlarged views in Figs. 3B and 6H . These figures have now been corrected, and the corrections do not change the conclusions of the study. The authors apologize for the error.Fig. 6HH&E stains of AOM/DSS mouse models with different treatment.View Large Image Figure ViewerDownload Hi-res image Download (PPT) Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal CancerStatins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR) inhibitors decreasing serum cholesterol and have shown promise in cancer prevention. In this study, we demonstrated the oncogenic role of HMGR in colorectal cancer (CRC) by disclosing increased HMGR activity in CRC patients and its enhancement of anti-apoptosis and stemness. Our previous studies showed that statins containing carboxylic acid chains possessed activity against histone deacetylases (HDACs), and strengthened their anti-HDAC activity through designing HMGR-HDAC dual inhibitors, JMF compounds. Full-Text PDF Open Access
SDGs
Type
corrigendum